WallStSmart

Merck & Company Inc (MRK)vsVSee Health, Inc. (VSEE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 454825% more annual revenue ($65.77B vs $14.46M). MRK leads profitability with a 13.6% profit margin vs -92.4%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

VSEE

Avoid

31

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: -6.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-62.3%)

Margin of Safety

-62.3%

Fair Value

$81.23

Current Price

$130.21

$48.98 premium

UndervaluedFair: $81.23Overvalued

Intrinsic value data unavailable for VSEE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$307.25B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

VSEE1 strengths · Avg: 10.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
35.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

VSEE4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$4.71M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-258.8%2/10

ROE of -258.8% — below average capital efficiency

Revenue GrowthGrowth
-4.9%2/10

Revenue declined 4.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : VSEE

The strongest argument for VSEE centers on Price/Book.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : VSEE

The primary concerns for VSEE are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while VSEE is a turnaround play — different risk/reward profiles.

VSEE carries more volatility with a beta of 0.49 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

VSee Health, Inc.

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

VSee Health, Inc. is a leading innovator in the telehealth sector, providing secure video communication solutions tailored for healthcare providers and patients alike. Its comprehensive platform enhances care delivery through features such as remote patient monitoring, asynchronous messaging, and seamless EMR integration, thereby bolstering efficiency and quality across various medical disciplines. As the demand for virtual care surges in the evolving healthcare landscape, VSee's commitment to patient engagement and accessibility positions it strategically for significant growth. With a focus on innovation and client success, VSee Health is well-prepared to capitalize on the expanding digital healthcare market.

Visit Website →

Want to dig deeper into these stocks?